[Lipid lowering therapy for primary prevention of coronary heart disease--pro lipid lowering therapy].
The high rate of coronary artery disease (CAD) mortality needs preventive intervention. Several studies have documented the effectiveness of LDL-cholesterol lowering in CAD primary prevention. The West of Scotland Prevention Study resulted in risk reduction by about one third through LDL-cholesterol lowering. The data indicate that specifically patients at high risk benefit from lipid reduction. High risk patients have besides high LDL-cholesterol one or more additional risk factors such as family history of premature coronary artery disease, hypertension, smoking, low HDL-cholesterol or diabetes. Therapy primarily aims at life style changes, secession of smoking and weight reduction as well as dietary changes to achieve LDL-cholesterol levels of 115-175 mg/dl (3-4.5 mmol/L), depending on the individual risk constellation. This strategy allows to reduce the number of patients needed to treat in order to prevent one CAD event (56 in isolated hypercholesterolemia) to 14-24 in high risk persons, approaching the number (n = 13) known for effective lipid lowering in secondary prevention of coronary heart disease. Given the fact that only one third of patients suffering from a myocardial is likely to survive the first year after the event, its time for physicians to identify patients at high risk for coronary artery disease. This LDL-cholesterol lowering in primary prevention is an important and successful approach in preventive medicine. The high risk strategy for coronary primary prevention has shown to be cost effective more or at least similar to the treatment of hypertension.
Steinmetz
A
A
Klinikum der Philipps-Universität Marburg Zentrum Innere Medizin Abteilung Kardiologie.
Noll
B
B
Maisch
B
B
Schäfer
J R
JR
D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D006937:Hypercholesterolemia / Q000401:mortality / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents
Lipidsenkende Therapie zur Primärprävention der koronaren Herzkrankheit--Pro lipidsenkende Therapie.